These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6336538)

  • 21. Homologous and hybrid calcium complexes of A23187 and hypoglycemic sulfonylureas: nuclear magnetic resonance and conformational analysis.
    Deleers M; Brasseur R; Gelbcke M; Malaisse WJ
    J Inorg Biochem; 1982 Jun; 16(3):215-25. PubMed ID: 6809893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic effects of hypoglycemic sulfonylureas. V. In vitro effects of sulfonylureas on mitochondrial adenosine triphosphatase activity.
    Debeer L; Mannaerts G; De Schepper PJ
    Biochem Pharmacol; 1974 Jan; 23(2):251-8. PubMed ID: 4273213
    [No Abstract]   [Full Text] [Related]  

  • 23. Actual problems of the hypoglycaemic sulfonylureas.
    Káldor A
    Ther Hung; 1977; 25(2):47-50. PubMed ID: 898117
    [No Abstract]   [Full Text] [Related]  

  • 24. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
    Panten U; Burgfeld J; Goerke F; Rennicke M; Schwanstecher M; Wallasch A; Zünkler BJ; Lenzen S
    Biochem Pharmacol; 1989 Apr; 38(8):1217-29. PubMed ID: 2650685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular basis of oral hypoglycemic sulfonylurea action].
    Owecki M; Horst-Sikorska W; Sowiński J
    Pol Merkur Lekarski; 2003 Nov; 15(89):445-8. PubMed ID: 14969140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes.
    Müller G; Geisen K
    Horm Metab Res; 1996 Sep; 28(9):469-87. PubMed ID: 8911985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Misunderstandings and controversies about the insulin-secreting properties of antidiabetic sulfonylureas.
    Henquin JC
    Biochimie; 2017 Dec; 143():3-9. PubMed ID: 28711685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular loci of sulfonylurea actions.
    Lebovitz HE
    Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct measurements of increased free cytoplasmic Ca2+ in mouse pancreatic beta-cells following stimulation by hypoglycemic sulfonylureas.
    Abrahamsson H; Berggren PO; Rorsman P
    FEBS Lett; 1985 Oct; 190(1):21-4. PubMed ID: 2412893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and relative hypoglycemic potencies of four sulfonylureas in man.
    WEST KM; JOHNSON PC
    Diabetes; 1960; 9():454-8. PubMed ID: 13784586
    [No Abstract]   [Full Text] [Related]  

  • 31. [40 years of using sulfonylurea derivatives for treatment of diabetes].
    Sieradzki J
    Przegl Lek; 1996; 53(9):641-6. PubMed ID: 8992529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular targets for antidiabetic sulfonylureas and potassium channel openers.
    Szewczyk A
    Biochem Pharmacol; 1997 Nov; 54(9):961-5. PubMed ID: 9374415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets.
    Kawazu S; Sener A; Couturier E; Malaisse WJ
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):277-83. PubMed ID: 6995864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparation and antidiabetic activity of new substituted 3,5-diarylpyrazolesulfonylurea derivatives. II: Structure-activity relationship.
    Soliman R; Faid-Allah HM; el-Sadany SK
    J Pharm Sci; 1987 Aug; 76(8):626-32. PubMed ID: 11002821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cells.
    Eliasson L; Renström E; Ammälä C; Berggren PO; Bertorello AM; Bokvist K; Chibalin A; Deeney JT; Flatt PR; Gäbel J; Gromada J; Larsson O; Lindström P; Rhodes CJ; Rorsman P
    Science; 1996 Feb; 271(5250):813-5. PubMed ID: 8628999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sulfonylureas and diabetes mellitus].
    Ascaso JF
    Med Clin (Barc); 1983 Sep; 81(7):302-4. PubMed ID: 6645672
    [No Abstract]   [Full Text] [Related]  

  • 37. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
    Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
    Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of the glycaemic effects of sulfonylureas.
    Ashcroft FM
    Horm Metab Res; 1996 Sep; 28(9):456-63. PubMed ID: 8911983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacological aspects of comparative studies on different blood sugar-lowering sulfonylureas].
    Beyer J; Haupt E; Cordes U; Sell G; Schöffling K
    Arzneimittelforschung; 1973 Nov; 23(11):Suppl:1668-75. PubMed ID: 4205544
    [No Abstract]   [Full Text] [Related]  

  • 40. New oral antidiabetic drugs. Synthesis and structure-activity relationships.
    Francia E; Marin A; Verdejo F; Sanchez MS; Morell J
    Boll Chim Farm; 1975 Jul; 114(7):379-92. PubMed ID: 1164447
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.